PYXS vs LLY vs PFE vs MRK vs BMY vs KO

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -14. 2% for Pyxis Oncology, Inc. (PYXS). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 5x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Pyxis Oncology, Inc. (PYXS) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

5x versus Eli Lilly and Company at 50. 6x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 1. 10x versus The Coca-Cola Company's 2. 26x — a reasonable growth-adjusted valuation.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +429.

1%, compared to -87. 3% for Pyxis Oncology, Inc. (PYXS). Over 10 years, the gap is even starker: LLY returned +1522% versus PYXS's -86. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

15β versus Pyxis Oncology, Inc. 's 1. 44β — meaning PYXS is approximately -1072% more volatile than KO relative to the S&P 500. On balance sheet safety, Pyxis Oncology, Inc. (PYXS) carries a lower debt/equity ratio of 35% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -14. 2% for Pyxis Oncology, Inc. (PYXS). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -574. 5% for Pyxis Oncology, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -609. 2% for PYXS. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 1. 10x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 8x forward P/E versus 31. 7x for Eli Lilly and Company — 22. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PYXS: 229. 3% to $5. 50.

In this comparison, PFE (6.

6% yield), BMY (4. 3% yield), MRK (2. 7% yield), KO (2. 5% yield), LLY (0. 5% yield) pay a dividend. PYXS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1522% 10Y return). Both have compounded well over 10 years (LLY: +1522%, PYXS: -86. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PYXS (Healthcare) and LLY (Healthcare) and PFE (Healthcare) and MRK (Healthcare) and BMY (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PYXS is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock; PFE is a mid-cap income-oriented stock; MRK is a large-cap deep-value stock; BMY is a mid-cap deep-value stock; KO is a large-cap quality compounder stock. LLY, PFE, MRK, BMY, KO pay a dividend while PYXS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.